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Background: The purpose of this analysis is to evaluate the safety and effectiveness of insulin initiation with
once-daily insulin detemir (IDet) or insulin glargine (IGlar) in real-life clinical practice in Turkish patients with type 2
diabetes mellitus (T2DM).
Methods: This was a 24-week multinational observational study of insulin initiation in patients with T2DM.
Results: The Turkish cohort (n = 2886) included 2395 patients treated with IDet and 491 with IGlar. The change in
glycosylated haemoglobin (HbA1c) from the pre-insulin levels was −2.21% [95% confidence interval (CI) −2.32, −2.09] in
the IDet group and −1.88% [95% CI −2.17, −1.59] in the IGlar group at the final visit. The incidence rate of minor
hypoglycaemia increased in both groups from the pre-insulin to the final visit (+0.66 and +2.23 events per patient year
in the IDet and IGlar groups, respectively). Weight change in the IDet group was −0.23 kg [95% CI −0.49, 0.02 kg],
and +1.55 kg [95% CI 1.11, 2.00 kg] in the IGlar group. Regression analysis with adjustment for previously identified
confounders (age, gender, duration of diabetes, body mass index, previous history of hypoglycaemia, microvascular
disease, number and change in oral anti-diabetic drug therapy, HbA1c at baseline and insulin dose) identified an
independent effect of insulin type (IDet versus IGlar) with a risk of at least one episode of hypoglycaemia (odds ratio
(OR): 0.33 [95% CI 0.21, 0.52], p <0.0001), and weight loss ≥1 kg (OR: 1.75 [95% CI 1.18, 2.59], p = 0.005), but not on
HbA1c (+0.05% [95% CI −0.15, 0.25%], p = 0.6).
Conclusions: Initiation of basal insulin analogues, IDet and IGlar, were associated with clinically significant glycaemic
improvements. A lower risk of minor hypoglycaemia and greater odds of weight loss ≥1 kg was observed with IDet
compared with IGlar.
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Many patients with type 2 diabetes mellitus (T2DM) ul-
timately require insulin to maintain glycaemic control.
Nonetheless, there is still considerable debate regarding
which insulin regimens are optimal to start the treat-
ment cascade of the disease [1]. Basal insulin is a widely
used treatment option for patients with T2DM at various
stages of disease progression [2]. Basal insulin formula-
tions have been continuously improved over the years
and have become widely used as they have many phar-
macodynamic and pharmacokinetic advantages over neu-
tral protamine Hagedorn (NPH) insulin including a longer
duration of action, reduced variable absorption profiles
and a reduced marked peak effect [3]. Insulin detemir
and insulin glargine are widely used as add-on ther-
apies for patients not responding to oral anti-diabetic
drug (OAD) regimens, but there are few studies directly
comparing the two insulin analogues in routine care [4-6].
The primary objective of this international observa-
tional study, SOLVE™, was to evaluate the safety and ef-
fectiveness of once-daily insulin detemir or glargine in a
real-life clinical setting in patients with T2DM failing
OAD therapy. The following is a sub-analysis of the local
SOLVE™ cohort in Turkey, the first observational study
comparing the effects of once-daily insulin detemir with




The present evaluation is a sub-analysis of the SOLVE™
study (clinical trial numbers NCT00825643 and NCT
00740519). This study was a 24-week, non-interventional,
international, multi-centre, open-label, prospective study
of insulin detemir initiation in patients with T2DM treated
with one or more OADs. SOLVE™ was conducted in 10
countries: Canada, China, Germany, Israel, Italy, Poland,
Portugal, Spain, the UK and Turkey. The study was con-
ducted in accordance with the Declaration of Helsinki
and Guidelines for Good Pharmacoepidemiology Practice
[7,8]. Ethical approval was obtained from local institu-
tional review boards or independent ethics committees
prior to commencement of the study in each of the par-
ticipating countries [9]. Initiation of insulin therapy was
entirely at the discretion of the treating physician accord-
ing to local clinical practice, and the study enrolled and
evaluated patients for whom this decision had already
been made. Results from the global study cohort have
been previously published [10,11].
In Turkey, the national regulatory requirements led to
the inclusion of patients prescribed either insulin dete-
mir or insulin glargine at least once daily, and thus pro-
vided an opportunity to compare the effects of the two
insulin analogues in patients with T2DM. Data werecollected during three routine clinic visits: a baseline
visit immediately upon initiating treatment with once-
daily insulin detemir or insulin glargine, an interim visit
at 12 weeks, and a final visit at 24 weeks. Any proce-
dures during the study period with regard to clinical
care delivered were entirely at the discretion of the par-
ticipating physician and the local practice in the investi-
gating centre.
Patients
The Turkish patient cohort was enrolled between April
2008 and October 2009. The inclusion and exclusion cri-
teria for the global SOLVE™ study have been described
elsewhere [11]. Patients already receiving one or more
OADs and commencing treatment with either insulin
detemir or insulin glargine within the previous 3 months
could be enrolled in the study at the discretion of the in-
vestigator. Patients receiving insulin treatment for more
than 3 months were excluded. Children below the age of
6 years and female patients who were pregnant, breast-
feeding or intending to become pregnant within 6 months
of the study initiation or who were not using adequate
contraceptive methods were also excluded from the study.
People with known or suspected allergy to insulin detemir
or insulin glargine and those receiving glucose-lowering
treatment other than diet, exercise or OAD before basal
insulin therapy were also excluded. To limit selection bias,
participating physicians were instructed to enrol patients
on a consecutive basis until each site met the recruitment
targets.
Patients could withdraw from the study at any time
without giving any specific reason. Those patients who
withdrew consent were not initiated on insulin at the
baseline visit, and those who had an informed consent
date after the baseline visit date, were excluded from the
Turkish cohort.
Endpoints
The primary goal for safety assessment was to evaluate
the incidence of serious adverse drug reactions (SADRs),
including major hypoglycaemic events, while using once-
daily insulin detemir or once-daily insulin glargine in rou-
tine clinical practice. Safety evaluation also included the
incidence of all daytime and nocturnal hypoglycaemic
events and all other reported adverse drug reactions
(ADRs).
ADRs were defined as any event for which a causal re-
lationship to insulin detemir or insulin glargine was sus-
pected, from the time the patient gave informed consent
until the patient completed the study. The event was de-
fined as serious if it resulted in any of the following:
death, a life-threatening experience, in-patient hospitali-
zation or prolongation of existing hospitalization for
more than 24 hours, a persistent or significant disability/
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important medical event that required medical or surgical
intervention to prevent one of the outcomes listed in this
definition. In this study, all episodes of major hypogly-
caemia were considered to be SADRs.
All episodes of hypoglycaemia were self-reported. Ma-
jor hypoglycaemia was defined as any hypoglycaemic
event requiring assistance from a third party. Minor
hypoglycaemia was defined as a blood glucose measure-
ment <56 mg/dL (3.1 mmol/L) with or without symp-
toms. The period of recall for major hypoglycaemia and
minor hypoglycaemia was 12 weeks and 4 weeks prior to
the follow-up visit, respectively. Hypoglycaemic events
were classified as nocturnal, if they occurred between
bedtime and getting up the next morning.
Efficacy was assessed through the evaluation of glyco-
sylated hemoglobin (HbA1c) and fasting blood glucose
(FBG) (mean, change from baseline). Other secondary
endpoints included: seven-point self-monitoring of blood
glucose (SMBG) profile (pre- and post-breakfast, pre- and
post-lunch, pre- and post-dinner, at night), body weight,
waist circumference, waist-to-hip ratio, systolic and dia-
stolic blood pressure, total cholesterol, low-density lipo-
protein cholesterol, high-density lipoprotein cholesterol,
triglycerides and insulin dose, and the use of OADs, anti-
hypertensive drugs and lipid-lowering drugs.
Statistical analysis
Patients using insulin detemir or insulin glargine at least
once daily and reporting safety information to the phy-
sician were included in the analyses of adverse drug re-
actions (ADRs) and hypoglycaemia (Full Analysis Set
[FAS]). Analyses of HbA1c, blood glucose and lipid pro-
files were based on a subset of patients with at least one
FBG, HbA1c, weight measurement or record of hypogly-
caemia at both baseline and final visit (Efficacy Analysis
Set [EAS]).
Continuous variables are summarized with descriptive
statistics (mean, standard deviation, 95% confidence in-
terval (CI)). Categorical variables are reported in fre-
quency tables (N,%). Statistical comparisons of pre- and
post-insulin initiation values were performed with paired
t-tests for continuous variables. Wilcoxon signed-rank
test was used to compare the rates of hypoglycaemic
events at baseline and final visit.
Regression models were used to evaluate the effect of
insulin type on final-visit HbA1c (general linear model),
occurrence of at least one episode of hypoglycaemia
from baseline to study end, and weight loss of at least
1 kg (logistic regression models). The weight model in-
cluded all parameters identified as being significant pre-
dictors of weight loss ≥1 kg in the analyses of the global
SOLVE™ cohort (data on file). This included gender, body
mass index (BMI) categories (<25 kg/m2, 25 to <30 kg/m2,30 to <35 kg/m2 and ≥35 kg/m2), number of OADs at
baseline and baseline HbA1c. The HbA1c and hypoglycae-
mia models included all parameters identified as being sig-
nificant predictors either of HbA1c at final visit or the
occurrence of at least one episode of hypoglycaemia in
analyses of the global cohort. These parameters included
age categories (<50 years, 50–75 years in 5-year intervals,
and ≥75 years), diabetes duration (in quartiles), BMI cate-
gories (as presented above), previous history of hypo-
glycaemia or microvascular disease, number and change
in OAD therapy at the time of insulin initiation, HbA1c at
baseline and insulin dose (IU in quartiles) [12]. All regres-
sion models included the additional variable of the insulin
type, to denote treatment with either insulin detemir or
insulin glargine.
For the evaluation of HbA1c and hypoglycaemia, two
sensitivity analyses were performed. The first included a
previous history of macrovascular disease in addition to
the above-mentioned parameters. The second was a more
basic model only adjusting for duration of diabetes, previ-
ous history of hypoglycaemia and baseline HbA1c. The re-
sults of the sensitivity analyses are available in Additional
file 1.
All analyses used two-sided tests with the criteria set
at α = 0.05.Results
A total of 2395 patients were enrolled in the insulin
detemir group. Thirteen subjects were excluded for the
following reasons: no insulin treatment (n = 4), informed
consent date after baseline visit date (n = 8) and with-
drew informed consent (n = 1). In the insulin glargine
group, 491 patients were enrolled and three were ex-
cluded because of missing documentation of insulin
treatment. The criteria for inclusion in the FAS were
met by 78.3% (n = 1865) patients in the insulin detemir
group and 70.9% (n = 346) in the insulin glargine group.
The criteria for inclusion in the EAS were met by 68.4%
(n = 1630) and 60.4% (n = 295) in the insulin detemir
and insulin glargine groups, respectively.
A total of 571 (30.6%) people in the detemir group dis-
continued the study for the following reasons: lost to fol-
low up (n = 355), OAD discontinued (n = 12), addition of
short-acting insulin (n = 31), study drug used twice daily
(n = 21), study drug discontinued (n = 27), other reasons
(n = 49) and missing data (n = 106). In the glargine
group, 155 (52.5%) people were withdrawn for similar
reasons: lost to follow-up (n = 85), OAD discontinued
(n = 4), addition of short-acting insulin (n = 9), study
drug used twice daily (n = 1), study drug discontinued
(n = 7), other miscellaneous reasons (n = 16) and missing
data (n = 40). Patients may have had more than one rea-
son for discontinuing the study.
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groups are shown in Table 1. Baseline mean age, gender,
weight, BMI, and previous medical history (including
previous episodes of hypoglycaemia) were not signifi-
cantly different between patients treated with insulin de-
temir and insulin glargine, and rates of hypoglycaemia
were low in both groups (0.37 and 0.59 events per pa-
tient year, respectively). The group of patients treated
with insulin detemir, however, had a significantly shorter
duration of diabetes (8.1 vs. 8.6 years, p = 0.03), and a
higher baseline HbA1c (9.7 vs. 9.2%, [83 vs. 77 mmol/mol]
p = 0.003) compared with patients treated with insulinTable 1 Baseline characteristics of patients initiated on











Age (years) 56.8 ± 10.2 56.6 ± 10.3 0.7979
Female (%) 57.2% 59.5% 0.3468
Duration of Diabetes (years) 8.1 ± 5.6 8.6 ± 5.4 0.0279
Weight (kg) 79.8 ± 13.9 78.5 ± 13.0 0.0606
BMI (kg/m2) 29.6 ± 4.8 29.6 ± 4.8 0.9541
Previous medical history (%)
Microvascular disease 30.0% 31.6% 0.4663
Macrovascular disease 21.3% 19.8% 0.4347
Hypoglycaemia 3.8% 3.9% 0.8940
HbA1c (%) 9.72 ± 1.74 9.24 ± 1.71 0.0033
HbA1c (mmol/mol) 83 ± 19 77 ± 19
FBG (mg/dl) 233 ± 75 221 ± 68 0.0989
FBG (mmol/l) 12.9 ± 4.2 12.3 ± 3.7
Rate of minor Hypoglycaemia
(events ppy)
0.37 0.59 0.0554
OAD Treatment at time of
Insulin Initiation (%)
Number of OADs 0.0214
1 OAD 29.6% 26.3%
2 OADs 45.0% 51.8%
>2 OADs 25.4% 21.8%
Class of OAD
Metformin 81.9% 86.7% 0.0100
Sulphonylureas 55.5% 52.0% 0.1611
Glinides 21.6% 26.1% 0.0279
Thiazolidinediones 20.2% 18.8% 0.4745
α-glucosidase inhibitors 18.0% 10.8% 0.0001
DPP-IV inhibitors 1.8% 2.7% 0.2441
Values are in mean ± SD or percentage.glargine. The number and type of OADs used prior to insu-
lin initiation also differed significantly between the groups,
with a higher proportion of patients using a single OAD
(30% vs. 26%) or >2 OADs (25% vs. 22%), in the group of
patients initiating with insulin detemir (Table 2).
Serious adverse drug reactions (SADRs) and adverse drug
reactions (ADRs)
SADRs, including major hypoglycaemia, were not reported
during the observation period in either treatment group.
A single ADR was reported in the insulin detemir group
(pruritus, skin and subcutaneous tissue disorder), and the
relationship of this ADR to insulin detemir was determined
as ‘probable’. It was documented that the condition recov-
ered, and that neither the therapy, nor the insulin dose
was modified.
Hypoglycaemia
The incidence rate of minor hypoglycaemia increased
significantly (p <0.001) in both groups from pre-insulin
to final visit (+0.66 and +2.23 events per patient year in
the detemir and glargine groups, respectively). Minor
daytime hypoglycaemic events per patient year were 0.30
at baseline and 0.84 at final visit for insulin detemir, and
0.59 at baseline and 2.42 at final visit for insulin glargine.
In the insulin detemir group, nocturnal hypoglycaemia
occurred at a rate of 0.07 and 0.25 events per patient
year at baseline and at final visit, respectively. In the in-
sulin glargine group, the rate of nocturnal hypoglycae-
mia was 0 and 0.16 events per patient year at baseline
and at final visit, respectively.
Insulin type was identified as an independent predictor
of the occurrence of one or more episodes of hypogly-
caemia during the study. After adjusting for the afore-
mentioned confounders, insulin detemir had an odds
ratio (OR) for hypoglycaemia of 0.33 [95% CI 0.21, 0.52,
p < 0.001] relative to insulin glargine (Figure 1a). The rela-
tionship between insulin type and risk of hypoglycaemia
during the study remained consistent in the sensitivity
analyses (see Additional file 1).Table 2 Key insulin treatment related endpoints of
patients on insulin detemir and insulin glargine at final





HbA1c (%) 7.48 ± 1.19 7.38 ± 1.24
HbA1c (mmol/mol) 58 ± 13 57 ± 14
FBG (mg/dl) 145 ± 44 139 ± 38
FBG (mmol/l) 8.0 ± 2.4 7.7 ± 2.1
Weight (kg) 79.5 ± 12.6 79.7 ± 12.2
Rate of Minor Hypoglycaemia (events ppy) 1.08 2.56
Insulin Dose (U/kg) 0.30 ± 0.13 0.31 ± 0.14
ba c
Figure 1 Effect of insulin type (insulin detemir versus insulin glargine) on (a) hypoglycaemia during the study, (b) weight loss of ≥1 kg
by final visit, and (c) final HbA1c. Footnote: Error bars indicate 95% confidence intervals.
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During the observational period, moderate weight loss
was observed in patients treated with insulin detemir,
with a mean change in weight of −0.23 kg [95% CI −0.49,
0.02]. In contrast, patients in the insulin glargine groupgained weight, with a mean weight change of +1.55 kg
[95% CI 1.11, 2.00]. Insulin type was identified as an inde-
pendent predictor for weight loss ≥1 kg during the study
after adjustment for known confounders (Figure 1b). In-
sulin detemir was associated with significantly greater
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p = 0.005]) relative to insulin glargine.
Total cholesterol changed from 5.4 ± 1.1 mmol/l at
baseline to 5.1 ± 1.0 mmol/l (change −0.4 mmol/l, [95%
CI −0.5, −0.2], p < 0.001) in the insulin detemir group, and
from 5.3 ± 1.1 mmol/l to 4.7 ± 0.9 mmol/l (change −
0.6 mmol/l, [95% CI −0.9, −0.3], p < 0.001) in patients
treated with insulin glargine. Triglycerides changed from
2.3 ± 1.3 mmol/l at baseline to 2.0 ± 1.0 mmol/l (change −
0.3 mmol/l, [95% CI −0.4, −0.1], p < 0.001) in the in-
sulin detemir group, and from 2.3 ± 1.2 mmol/l to 1.9 ±
0.9 mmol/l (change −0.4 mmol/l, [95% CI −0.6, −0.1],
p = 0.01) in the insulin glargine group.
Efficacy outcomes
Results showed no major difference in HbA1c values du-
ring the observational period between insulin glargine and
insulin detemir (Table 1). At the final visit, HbA1c had
changed significantly (p <0.001) from the pre-insulin levels
by −2.21% [95% CI −2.32, −2.09] (−24 mmol/mol
[95% CI −25, −23]) in the insulin detemir group, and
by −1.88% [95% CI −2.17, −1.59] (−21 mmol/mol
[95% CI −24, −17]) in the insulin glargine group. Fasting
blood glucose (FBG) also changed significantly (p <0.001)
from baseline to study end by −90 mg/dL [95% CI −97, −
83] (−4.99 mmol/l [95% CI −5.38, −4.60]) in the insulin
detemir group, and by −83 mg/dL [95% CI −98, −68]
(−4.61 mmol/l [−5.42, −3.79]) in the insulin glargine
group. All SMBG values improved significantly (p <0.05)
over the study period in both patient groups (data not
shown).
Regression analysis did not show insulin type to have
an independent effect on the final HbA1c value, with a
difference of +0.05% [95% CI −0.15, +0.25%, p = 0.6]
(+0.5 mmol/mol [95% CI −1.6, +0.25]) for insulin dete-
mir relative to insulin glargine after adjustment for known
confounders (Figure 1c). The relationship between insulin
type and change in HbA1c during the study remained con-
sistent in the sensitivity analyses (see Additional file 1).
Insulin dose
Baseline and final doses of insulin detemir and insulin
glargine were similar. The mean baseline dose was 0.21
U/kg for both insulin types, and the mean dose at final
visit was 0.30 U/kg for insulin detemir and 0.31 U/kg for
insulin glargine.
Discussion
This international multicentre observational study was
performed to document the safety and effectiveness of
once-daily insulin detemir and insulin glargine in pa-
tients with T2DM managed in a real-life clinical practice
setting in Turkey. The total incidence of ADRs in the
population of 2,886 Turkish patients was low; with onlyone ADR observed during the 24-week study, and no
SADRs or major hypoglycaemic episodes, despite signifi-
cant improvements in glycaemic control.
According to a prospective 6-year follow-up study in a
representative sample of Turkish men and women, the
annual incidence rate of T2DM was 11.0 and 12.4 per
1000 person-years in women and men, corresponding to
300,000 incident cases annually [13]. A recently published
report estimated the prevalence of diabetes in Turkey in
people aged over 20 years to be 16.5%, nearly half (45.5%)
of whom were newly diagnosed [14]. Another multi-
national survey of 100 physicians in Turkey examining the
perceived role of healthcare providers in tackling T2DM
and the challenges they face, particularly regarding insulin
treatment also found that most physicians had seen an in-
crease in the number of T2DM patients over the previous
5 years, and almost all participating physicians agreed that
the burden of diabetes was increasing [15]. Despite the
high prevalence of diabetes in Turkey, most primary care
physicians rarely initiate, modify or intensify insulin ther-
apy, with the lack of experience and time to educate pa-
tients often being cited as the main barriers [15].
The Turkish part of the SOLVE™ study involved more
than 200 participating physicians, and all treatment deci-
sions were made at the discretion of the physician in ac-
cordance with patient’s clinical requirements. Thus, the
treatment of patients within the study may be consid-
ered to reflect real-life clinical practice in Turkey. Base-
line demographic data indicate inadequate glycaemic
control and delayed insulin initiation. The mean baseline
HbA1c (approximately 9.5%) was well above the level of
7.0% recommended by the American Diabetes Associ-
ation (ADA) [16]. Of all the countries participating in
the SOLVE™ study, Turkey had the highest proportion of
patients with a baseline HbA1c ≥9.0% [10]. The mean dia-
betes duration of over 8 years at baseline also suggests de-
layed insulin initiation in this study population.
Basal insulin is a convenient and simple way to initiate
insulin treatment in patients with T2DM. While there is
general agreement that the currently available basal in-
sulin analogue formulations are superior to human NPH
insulin, in particular with respect to the risk of hypogly-
caemia [17], there is no consensus as to which of the two
available basal analogues should be recommended to initi-
ate insulin treatment and what the potential differences
are, if any, in patients with T2DM.
According to our knowledge, this is the first prospective
non-interventional study to compare the effects of insulin
detemir and insulin glargine in the real-life clinical envir-
onment. Several studies have compared either insulin
detemir or insulin glargine with NPH insulin [18,19], but
there are few studies directly comparing both basal insulin
analogues [20,21]. Consistent with our findings, most
head-to-head treat-to-target trials have not shown a
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on HbA1c [20-22]. The only outlier is a recently published
study by Meneghini et al. [23], which failed to confirm
non-inferiority for insulin detemir versus insulin glargine.
The lower than expected HbA1c reductions in both groups
(−0.48% for insulin detemir and −0.74% for insulin glar-
gine) may be partly explained by the discontinuation of all
OADs except metformin, without corresponding metfor-
min dose adjustment and infrequent insulin dose titration.
Our safety results are consistent with other studies of
once-daily insulin detemir initiation, both randomised
controlled trials [24-26] and observational studies [27,28]
in patients not responding to OAD therapy. These studies
have consistently shown that insulin detemir has a good
safety profile and a low incidence of hypoglycaemia. Ran-
domised controlled trials comparing insulin detemir and
insulin glargine have not reported significant differences
in overall nocturnal and major hypoglycaemia rates
[21,22], except for Meneghini et al. [23] where insulin
detemir was associated with a significantly lower overall
rate of hypoglycaemia. In this study, we report an inde-
pendent effect of insulin type on the risk of minor hy-
poglycaemic episodes. As titration in this study was at the
treating physicians’ discretion, the difference in the inci-
dence of hypoglycaemia in favour of the insulin detemir
group may be partly because of the varying up-titration
between the two groups and the slightly higher HbA1c
values at final visit (7.48% vs. 7.38%) in patients treated
with insulin detemir. However, reduced intra-patient glu-
cose variability seen in patients treated with insulin de-
temir may also play a role [29-31]. Unlike some of the
previous randomised controlled trials, where final insulin
dose was found to be greater for insulin detemir com-
pared with insulin glargine at the final visit [21-23], our
data indicate similar end-of-study dose values between the
two insulin analogues.
In the present study, insulin detemir also demonstra-
ted a favourable weight-sparing effect, and was associ-
ated with higher odds (1.75-fold) of weight loss ≥1 kg
compared with patients in the insulin glargine group.
Actual mean weight change among insulin detemir pa-
tients was negative in contrast to insulin glargine-treated
patients where the average weight increase was 1.5 kg.
These results are consistent with previously reported
randomised controlled trials and observational study re-
sults showing a trend toward less weight gain in patients
administered with insulin detemir [20-22,27,28,32]. The
mechanism for the weight-sparing effect of insulin dete-
mir is still not fully understood, but might be due to dif-
ferences in albumin binding, liver sensitivity, glucose
variability and hypoglycaemia, or satiety signalling [33].
The SOLVE™ study has several important limitations that
have been described elsewhere [11]. Because the study was
not randomised, it is not possible to differentiate betweenthe effects of treatment and other study or demographic
variables on clinical outcomes, and therefore, the results of
this study should be interpreted with caution. While the re-
gression models were used to control for various known
confounders, additional factors such as the speed of insulin
up-titration, dose and type of combination OAD therapy
and other variations in local clinical practice, may also have
influenced the efficacy and safety of these two basal insulin
analogues. Patients were recruited into the study after they
were deemed to be candidates for once-daily insulin
detemir or once-daily insulin glargine as add-on therap-
ies to OADs based on the decision of the study phys-
ician according to local clinical practice. The percentage
of patients lost to follow-up in the Turkish cohort (in
both insulin detemir and glargine groups) was larger
than for the total SOLVE™ cohort [11]. Both the recruit-
ment and the loss to follow-up infer selection bias. In
addition, whereas the recall of severe hypoglycemia ap-
pears to be preserved for a period of up to 1 year, the
reliability of recall of episodes of mild hypoglycemia is
unknown in patients with T2DM, and may be subject
to recall bias [34]. The definitions of hypoglycemia
(<56 mg/dL or 3.1 mmol/L) are consistent with other
studies involving insulin detemir, and is a level at which
autonomic symptoms of hypoglycemia are known to
occur [35].
Conclusion
The results from the SOLVE™ cohort in Turkey are con-
sistent with previously reported randomised clinical tri-
als and non-investigational study data of insulin detemir
with regard to effective glycaemic control, low incidence
of hypoglycaemia and a weight-sparing effect. Compared
with T2DM patients initiated on insulin glargine in
Turkey, insulin detemir was associated with a similar le-
vel of glycaemic control, but a lower risk of hypoglycae-
mia and greater odds of weight loss, after correction for
a number of known confounders. This observational
study provides useful additional information on the im-
plementation and benefits of long-acting insulin ana-
logues in a real-life clinical setting of Turkish patients
with T2DM.
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